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Abstract
Background: It has been proposed that the immune system could be primed as early as during the fetal life and this might
have an impact on postnatal vaccination. Therefore, we addressed in murine models whether gestational treatment with
mycobacterial antigens could induce better immune responses in the postnatal life.
Methods/Findings: BALB/c mice were treated subcutaneously (s.c.) at the second week of gestation with antigen (Ag)85A
or heparin-binding hemagglutinin (HBHA) in the absence of adjuvant. Following birth, offspring mice were immunized
intranasally (i.n.) with the same antigens formulated with the adjuvant cholera toxin (CT) at week 1 and week 4. One week
after the last immunization, we assessed antigen-specific recall interferon gamma (IFN-c) responses by in vitro restimulation
of lung-derived lymphocytes. Protection against infection was assessed by challenge with high dose Mycobacterium bovis
Bacille Calmette-Gue ´rin (BCG) given i.n. We found that recall IFN-c responses were higher in the offspring born to the
treated mother compared to the untreated-mother. More importantly, we observed that the offspring born to the treated
mother controlled infection better than the offspring born to the untreated mother. Since the gestational treatment was
done in absence of adjuvant, essentially there was no antibody production observed in the pregnant mice and therefore no
influence of maternal antibodies was expected. We hypothesized that the effect of maternal treatment with antigen on the
offspring occurred due to antigen transportation through placenta. To trace the antigens, we conjugated fluorescent
nanocrystals with Ag85A (Qdot-ITK-Ag85A). After inoculation in the pregnant mice, Qdot-ITK-Ag85A conjugates were
detected in the liver, spleen of pregnant females and in all the fetuses and placentas examined.
Conclusion: The fetal immune system could be primed in utero by mycobacterial antigens transported through the
placenta.
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Introduction
Mycobacterium bovis Bacille Calmette-Gue ´rin (BCG) has been
used widely as a vaccine against tuberculosis (TB) since 1921.
Unfortunately, failure of BCG vaccination has been reported due
to poor and variable efficacy against adult pulmonary TB [1].
Apart from these limitations, neonatal BCG vaccination has a
number of adverse effects, i.e. systemic BCGosis, a rare but severe
consequence of BCG vaccination in children with immune
deficiencies or HIV infection [2]. Consequently, the development
of an effective vaccine, either a modified form of BCG or a
replacement of BCG vaccine suitable for the neonatal period of
vaccination is of utmost importance.
In general, an effective vaccination of newborns represents a
major challenge; given the fact that the neonatal immune system
is not fully matured and therefore not ready to respond to
vaccination in an efficient manner. Neonatal T cell responses are
suboptimal both qualitatively and quantitatively as suggested by
Sarzotti et al [3]. Compared to the adults, neonates are reported to
be aberrant in their cellular immune responses, often biased to
develop Th2 type immune responses and decreased ability to
generate Th1 type immune responses [4,5]. However, it has been
proposed that neonatal T cells from both humans and mice, are
able to mount a mature Th1 response provided that the
magnitude of costimulatory signals is increased [reviewed in ref.
5]. BCG vaccine is one of the classic examples that can alter the
unresponsiveness of the neonatal immune system upon vaccina-
tion, resulting in a robust Th1 type of immune response [6,7].
Moreover, vaccines formulated with the strong Th1-promoting
agent CpG motif or IC31 adjuvant [6,8] or vaccines delivered via
mucosal route could impact on early-life vaccination strategies
[9,10].
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onset of sensitisation of the fetal immune system might be possible in
utero [11–13]. In humans, prenatal exposure to helminth or
mycobacterial antigens has been shown to lead to better cytokine
responses in neonates [11]. Also, a memory T cell phenotype was
observed upon restimulation in vitro of cord blood mononuclear cells
with various allergens suggesting that T cell priming might occur in
utero [14]. Of interest is that depending on the conditions of antigen
exposure, neonates could respond differently ranging from deficient
to fully matured forms of immune responses [reviewed in ref. 6].
However, even if it is suggested that in utero sensitization may occur
due to transplacental transfer of antigens [15], it is still uncertain
how the fetal immune system gets primed with the antigen.
The aim of our study was to understand how the prenatal
sensitisation occurs and its impact on the development of a new TB
vaccine. We have tested two mycobacterial protein antigens namely
antigen (Ag)85A and the native form of mycobacterial heparin-
binding hemagglutinin (nHBHA) for immunization. Both nHBHA
and Ag85A have been evaluated as TB vaccine candidates in adult
animal models [16–19]. It has been shown that only native but not
recombinant (r) HBHA could induce protective immune responses
[16]. Ag85A is one of the major secretory proteins that has been
tested in clinical trials as a booster vaccine and reported to be safe
and immunogenic [20].
Our hypothesis was that maternal gestational treatment with
antigen could result in priming of the fetal immune system and that
subsequent immunization during the postnatal life may increase
neonatal immunity. We reported herein that exposure to mycobac-
terial antigens during the gestational period leads to antigen
transportation from the mother to the fetus and this resulted in an
early priming of the fetal immune system. Immunization with the
sameantigen during the postnatal life increased antigen-specific recall
interferon gamma (IFN-c) responses and protection against infection.
Results
Maternal treatment with antigen increases postnatal
cellular immune responses but shows no effect on
humoral immune responses
To follow the antigen-priming effect from the fetal age, we
treated a group of pregnant mice at the 2
nd week of pregnancy
with Ag85A given alone via subcutaneously (s.c.). Following birth,
offspring mice were immunized twice at week 1 and week 4 with
the same antigen plus adjuvant administered intranasally (i.n.).
One week after the last immunization, lung lymphocytes were
isolated and restimulated in vitro with Ag85A in order to assess the
recall IFN-c responses in the culture supernatants. As shown in
Table 1, offspring born to the treated mother had significantly
higher recall immune responses to Ag85A than the offspring born
to the untreated mother (Group 1 versus Group 3). In contrast,
maternal treatment did not show any significant influence on
serum antibody responses in the offspring.
In order to investigate whether the breast milk of a treated
mother had any influence on postnatal immune responses, a group
of newborn mice born to the treated mother was nursed by a foster
mother (Table 1, Group 2) until the weaning period. Results
showed that gestational priming enhanced recall responses
regardless of the condition of postnatal nursing (Table 1, Group
2), which were comparable to the group nursed by their own
mother (Table 1, Group 1). Antigen-specific IgM and IgG levels in
serum samples were similar between the groups. Neither cytokine
levels nor antibody levels were significantly enhanced by postnatal
nursing delivered by the treated mother (data not shown).
Finally, we checked the immune responses in a group of adult
mice treated similarly to the pregnant mothers. We observed that
treatment with the antigen in absence of adjuvant did not induce
any detectable IgG responses (Fig. S1). To induce a detectable IgG
response, Ag85A had to be provided together with the adjuvant
(Fig. S1).
Transplacental transfer of antigen from the mother to the
fetus
Prior to examine the translocation of antigens by injecting
Qdot-ITK-Ag85A to pregnant mothers, we injected plain Qdot-
ITK s.c. and followed their in vivo distribution. Qdot-ITK were
detected mainly in the skin, liver, and spleen. Qdot-ITK
fluorescence in the skin decreased with time (Fig. 1a, b, c). In
the spleen and liver, fluorescence signals increased from 24 h to
48 h post injection (Fig. 1d, e).
To follow the transfer of antigen from the mother to the fetus, we
injected the conjugate Qdot-ITK-Ag85A in pregnant mice at day
11 of gestation. Forty-eight hours postinjection, tissue specimens
Table 1. Effect of prenatal treatment on postnatal immune responses.
Prenatal Postnatal
Groups
Gestational
treatmenta
Immunization
(26)b
Nursing
motherc Immune responses
IFN-c (pg/ml) IgM (O.D.) IgG (O.D.)
Exp. 1 1 ++ Ag+ 16946167
* 0.7360.05 1.0160.04
2 ++ Ag2 1736624
* 0.6760.03 0.8660.12
3- + Ag2 1045630 0.6360.06 0.7860.06
Exp. 2 1 ++ Ag+ 3358679
* 0.5460.17 0.4460.09
2 ++ Ag2 33086616
* 0.6860.22 0.3260.03
3- + Ag2 18666499 0.5260.06 0.4060.04
aPregnant mother at the 2
nd week of gestation received Ag85A administered via s.c.
bOffspring mice were immunized twice with Ag85A at week 1 and week 4.
cOffspring mice were breastfed by treated (Ag+) or untreated (Ag2) mother immediately after birth until the weaning period.
O.D. values represent mean6s.d. of three mice with 1:1600 dilution.
Data for IFN-c represent mean6s.d. of triplicates prepared from pooled samples (3–4 mice/group).
*, p,0.05 when Group 1 or 2 compared with Group 3.
doi:10.1371/journal.pone.0009699.t001
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Fig. 2, Qdot-ITK fluorescence was detected in maternal organs and
in all placentas and fetuses analyzed. (Fig. 2c, d).
To check whether treatment with Qdot-ITK-Ag85A resulted in
priming of the fetal immune system, separate groups of pregnant
mice were allowed to give birth and postnatal immunization was
performed as described above. Similarly, Ag85A-specific recall
IFN-c responses were also increased in the offspring mice born to
the Qdot-ITK-Ag85A-treated mother (Fig. 2f).
Gestational treatment leads to higher levels of protection
against mycobacterial infection in the postnatal age
In order to investigate whether the increased postnatal
responses could have an impact on protection against infection
later in life, we chose mycobacterial nHBHA for immunization of
mice. nHBHA is one of the few antigens that has been tested in
animal models and found to provide a level of protection similar to
that seen after BCG vaccination [16]. Although rHBHA is not a
protective antigen, upon immunization, both forms of HBHA
could induce a comparable level of immune responses in vitro [16].
Thus, to assess antigen-specific memory responses, mice were
immunized with rHBHA and antigen-specific recall immune
responses were determined. Results from this study showed that
like Ag85A, prenatal treatment with rHBHA could induce higher
immune responses in the offspring compared to the control group
born to the mother untreated gestationally (Fig. 3).
To examine the level of protection, separate groups of mice
vaccinated with nHBHA were challenged with a high dose of
BCG (10
7 CFU) given i.n., and 3 weeks postchallenge the bacterial
burden in the lungs was determined. As shown in Table 2, the
Figure 1. In vivo Qdot distribution. Adult mice (3 animals per group)
wereinjectedwithQdot-ITK(120 pmol/mouse)vias.c.Miceweresacrificed
at several time points (3 h, 24 h and 48 h) post-injection and skin, kidneys,
liver, lungs and spleen were collected and embedded in OCT. Sections
were fixed, mounted and observed under green light in a fluorescence
microscope. Qdot-ITK fluorescence was detected in skin slides at 3 h (a),
24 h (b) and 48 h (c) post inoculation, and in slides from the spleen (d) and
the liver (e) at 48 h post inoculation. Magnification 1006.
doi:10.1371/journal.pone.0009699.g001
Figure 2. Distribution of Qdot-ITK-Ag85A in mother and fetuses. Pregnant mice (3 animals per group) were injected with Qdot-ITK-Ag85A
(120 pmol/mouse) via s.c. Mice were sacrificed 48 h post inoculation and mother organs as well as fetuses and placentas were removed and
embedded in OCT. Sections were fixed, mounted and observed under green light in a fluorescence microscope. Qdot-ITK-Ag85A fluorescence was
detected in the skin (a), placenta (b) and fetuses (c, d). Magnification 1006. Prior to the inoculation, Qdot-ITK-Ag85A were run in a 0.5% agarose gel
(e) to check conjugation. Lane 1, unconjugated Qdot-ITK; lane 2, Qdot-ITK-Ag85A. Recall IFN-c responses after in vitro restimulation of lung cells with
Ag85A were measured in the offspring born to the mother that received Qdot-ITK-Ag85A or Qdot-ITK (f).
doi:10.1371/journal.pone.0009699.g002
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could control infection better than the offspring born to the
untreated mother (Group 2 versus Group 3, p,0.01). The effect of
maternal priming was less clear in the group that received BCG
instead of nHBHA at 1-week and boosted later with nHBHA (data
not shown).
Discussion
Even if certain vaccination protocols can provide protection
during the neonatal period, frequently, successful vaccination is
compromised by the poorly developed immune system in neonates
[21]. This is unfortunate and leaves newborns exposed to infection
during a sensitive period in their lives. To improve this situation,
two strategies have been proposed namely, immunization of the
pregnant mother allowing the transfer of specific antibodies
through the placenta and milk and early priming of the fetal
immune system by in utero exposure to foreign substances. The
relevance of the first strategy is widely accepted [22,23] but it has
been questioned whether the fetal immune system could be
primed by simple exposure to the antigens or if various maternal
immune factors could contribute to the priming effect. The aim of
the present study has been to investigate this issue.
In this study we have shown that mycobacterial antigens
administered to the mother during the 2
nd week of gestation were
transported to the fetus through the placenta and that offspring
born to the treated mother displayed higher specific T cell
responses compared to the offspring born to the untreated mother.
Moreover, this first group of mice was more efficient in controlling
bacterial growth upon i.n. infection with BCG.
The maternal treatment was done under suboptimal immuni-
zation conditions since the antigens were administered in the
absence of adjuvant. As expected, no specific antibodies could be
observed in the serum of the treated animals unless the antigen
was given twice and formulated together with CT as adjuvant.
Under these conditions, protection in the offspring may be
attributed more to the transfer of antigen than to the transfer of
antibodies from the mother to the fetus. In addition of having
antigens transferred through the placenta, maternal gestational
treatment could also result in antigen transfer via mother’s milk
[24]. In this study, we did not directly monitor antigen transfer
from the mother to the neonates through the milk, however,
antigen-specific recall responses in the offspring mice were not
affected due to postnatal nursing provided by foster mothers
(untreated).
Figure 3. Maternal treatment increases postnatal cellular immune responses. Pregnant mice at 2
nd week of gestation were treated with
rHBHA via s.c. Following birth, neonates were immunized twice i.n. with rHBHA formulated with CT at week 1 (W1) and week 4 (W4). One week after
the last immunization, lung cells from the rHBHA-immunized animals were re-stimulated in vitro with rHBHA to measure recall IFN-c responses. Data
show mean IFN-c 6 s.d. of triplicate wells prepared from pooled samples (3–4 mice/group). Results were analyzed from two independent
experiments. p value (s) was calculated by comparing two groups using t test. * significant when p,0.05.
doi:10.1371/journal.pone.0009699.g003
Table 2. Bacterial burden in the lungs of offspring mice born
to the mother treated with or without nHBHA.
Treatment/Vaccination Protection
Groups
Pregnant
Mother Neonates
CFU in the lungs
mean6sd 6104
%o f
reduction
Week 1 Week 4
1 - BCG - 3.9560.6 21
2 nHBHA nHBHA+CT
nHBHA+CT
3.1560.7 37
**
3 - nHBHA+CT
nHBHA+CT
4.4060.6 12
4 - - 5.0060.7 -
Data show bacterial counts from individual animals and the mean. Four animals
per group from two independent experiments are depicted. Values shown are
the percent of reduction of CFU, calculated with respect to the PBS-control
group.
**, p,0.01 when Group 2 versus Group 3.
Not significant when Group 1 versus Group 2.
doi:10.1371/journal.pone.0009699.t002
Prenatal Priming
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transported from the mother to the fetus through placenta since
antigens conjugated with fluorescent Qdot were visible on the
placental tissue as well as on the fetal tissue. However, we do not
have any data about the organ distribution of antigen in the fetus.
This may be worth to consider for future studies. Our findings
corroborate earlier observations in humans where it was
postulated that prenatal exposure to antigens alters fetal immunity
[11,25–27]. However, in those studies, it was not possible to
evaluate the effect of antigen alone since the long period of human
pregnancy complicated the issue. The immune response of the
mother and the influence of transfer of specific antibodies through
the placenta or by milk could not be disregarded.
We observed here only a priming of the T cell compartment. In
mice and rats, the appearance of B cells is delayed compared to
the T cells and no B cells have been observed before birth.
Demarcation of splenic architecture takes place by day 6 and
germinal centers are observed between days 21 and 28 after birth.
In contrast, fetal thymocytes are able to proliferate in response to
T cell mitogens by day 17 of gestation [28]. This may explain why
only T cell and no B cell priming effect was observed upon
exposure to antigen delivered to the pregnant mothers at week two
of the gestation time. T cell development is completed in mice
immediately before birth and only a few mature CD4 and CD8 T
cells appear during this time which makes it difficult to analyze the
type of memory cells developed after gestational treatment [29]. In
humans, small numbers of B and T cells are already present in the
fetal liver and the architecture of the spleen is demarcated by week
26 of gestation. Thus, before birth, humans have relatively well
functional B and T cells which is not the case in mice and rats
[28]. Consequently, priming of human fetal B cells may be
achieved by exposure to antigen: certain evidence has already
been provided as in the case of maternal immunization with
tetanus toxoid during pregnancy [26]. Also, the priming of human
T cells in utero has been demonstrated since cord-blood cells from
PPD-sensitized mothers produced more antigen-specific cytokines
compared to cord-blood from unsensitized mothers [11].
We can conclude that gestational priming favoured the
induction of Th1 type responses in mice as evident by the
increased levels of IFN-c and a better control of infection, which
was comparable to the BCG-vaccinated control group. Thus, our
observations support, at least for these two mycobacterial protein
antigens, that prenatal immunization can sensitize the fetal
immune system by transplacental transfer of antigens. Conse-
quently, antigen specific T cell responses were increased following
postnatal immunization suggesting that this approach does not
induce tolerance in the neonates. Recently, Malhotra I et al
demonstrated that prenatal exposure to helminth and mycobac-
terial antigens does not induce tolerance but could enhance
cytokine responses in human fetus [11].
The basic significance of this current study lies on the fact that
prenatal immunization might impact on the maternal-fetal interac-
tion and such manipulation could contribute to the subsequent
responsesto postnatalimmunization.The criticalfactormightbethe
time point of gestational priming, which has been described in
several previous studies [24,26,30]. In humans, it has been proposed
that a cut-off level greater than 22 weeks gestation favors in utero
sensitisation with allergens [30]. Similarly, Gill TJI et al suggested
that transplacental immunization of human fetus occurs during fifth
to eight months of pregnancy [26]. This approach might provide
new insights into the development of TB vaccines especially for the
people who are at risk of adverse situation upon BCG-vaccination.
Another aspect of importance may be the route of antigen
administration. Subcutaneous delivery of the antigen may be
crucial due to the presence of various types of professional antigen
presenting cells such as DCs and Langerhans cells in the region
[31]. These cells may be responsible for the transport and efficient
presentation of the antigen from the mother to the fetal immune
system. In this study, offspring mice were immunized via i.n. in
order to induce a better protection in the respiratory tract.
Mycobacterium has a preferential tropism for the lungs and in fact,
tuberculosis is primarily a lung disease. We and others have shown
that i.n. immunization is better than systemic immunization to
evoke protective immune responses in the respiratory tract
[32,33]. Thus, we considered more important to study immune
responses and bacterial growth after infection in the lungs.
We conclude that prenatal priming of the fetal immune system
via transplacental transfer of antigens is possible and that this
treatment could educate the immune system of the neonates to be
ready for vaccination immediately after birth. This way of
vaccination might contribute significantly to the strategy being
used currently towards the development of new vaccines and
perhaps meet the needs for a successful neonatal vaccination.
Materials and Methods
Mice
The studies were performed using adult (10 weeks), neonatal (1
week) and infant (4 to 6-weeks) BALB/c mice. Adult mice were
purchased from Taconic Europe, Denmark or Scanbur AB,
Sweden and housed in pathogen free conditions. Neonates were
obtained from laboratory breeding facilities followed by timed
(hand) mating (for 24 hours) protocol using adult males and
females manually placing them together for an over night period.
Three weeks after birth, mice were weaned and separated from
their mothers. All animals were kept at the Animal Department of
the Arrhenius Laboratories, Stockholm University, Sweden. All
experiments were done in accordance with the ethical guidelines
available at Stockholm University. Mice were supervised daily and
sentinel mice were used to assess and ensure pathogen free
conditions in the facility.
Antigens and adjuvants
Recombinant Ag85A was obtained from LIONEX Diagnostics
& Therapeutics GmbH, Germany. Both n- and rHBHA were
kindly provided by C. Locht, Pasteur de Lille, France. Briefly,
nHBHA was extracted from Mycobacterium tuberculosis or M. bovis
and purified by heparin-sepharose chromatography [34], followed
by high-performance liquid chromatography (HPLC) as described
previously by Masungi et al [35]. rHBHA was expressed in
Escherichia coli and purified by nickel chromatography as previously
described [36]. Adjuvant, cholera toxin (CT) was obtained from
Quadratech Ltd, Surrey, UK.
Mycobacteria
M. bovis BCG (Pasteur strain) obtained from A. Williams, HPA,
Salisbury, UK was grown in Middlebrook 7H9 (DIFCO, Sparks,
MD, USA) broth supplemented with albumin-dextrose-catalase
(ADC), 0.5% glycerol and 0.05% Tween 80 (vol/vol). BCG was
collected at a log phase of growth (absorbance 1.0 measured at
OD600) for a culture period of 10–15 days at 37uC. Aliquots were
frozen in phosphate buffer saline (PBS) with 10% glycerol and kept at
270uC. Three vials picked randomly from the stock were thawed,
serially diluted in plating buffer (PBS with 0.05% Tween-80 [vol/
vol]) and colony forming units (CFU) counted 2–3 weeks after plating
on Middlebrook 7H11 agar (Karolinska Hospital, Solna, Sweden)
prepared with glycerol,oleicacid-albumin-dextrose-catalase (OADC)
and antibiotics; polymyxin B and amphotericin B.
Prenatal Priming
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As shown in Table 3, pregnant mice 14 days post mating (2
nd
week of gestation) were treated once with Ag85A or HBHA
(10 mg/mouse) formulated in PBS administered s.c. at the dorsal
neck region. A control group of pregnant mice received PBS. After
birth, mice were immunized twice i.n. with Ag85A or HBHA, at
week 1 (2 mg Ag85A or 1 mg HBHA formulated with 0.2 mgC Ti n
5 ml of PBS/mouse) and week 4 (10 mg Ag85A or 5 mg HBHA
formulated with 1 mgC Ti n2 0ml of PBS/mouse). A group of
newborn mice from Ag85A-treated mother was nursed by the
PBS-treated mother and vice versa (Table 3). One week old mice
received a dose which was five-times lower than that prepared for
4 weeks old mice. Mice were anesthetized with isofluorane (Baxter
Medical AB, Kista, Sweden) and 5 ml of the formulation was
delivered per nostril for a total of two doses. Mice were allowed to
breathe the suspension into the lungs naturally. Immunization at
week 1 was performed without the use of isofluorane. One week
after the last immunization, mice were sacrificed and blood and
lungs were collected.
To assess for the lack of antibody production by the antigen-
treated pregnant females, a separate group of adult mice was given
Ag85A without adjuvant. Primary and secondary specific antibody
responses were monitored in the serum up to week 2 for the
primary responses and one week after the last immunization for
the secondary responses. The immunogenicity of Ag85A was
evaluated when the antigen was provided in the presence of CT as
adjuvant. Secondary responses were measured also one week after
the last immunization.
Infection and bacterial counts in organs
Four weeks after the last immunization of the offspring with
nHBHA, mice were challenged with a high BCG dose (10
7 CFU)
i.n. Three weeks after infection, lungs were removed aseptically.
The organs were homogenized by using a glass homogenizer.
Organ homogenates were diluted serially and plated on Mid-
dlebrook 7H11 agar plate and incubated at 37uC for 2–3 weeks.
Following incubation, bacterial counts were enumerated and
expressed as CFU per organ.
Quantum dot conjugation and in vivo administration
Poly-ethylene-glycol coated quantum dots (Qdot-ITK) that emit
light at 655 nm were purchased from Invitrogen and stored at 4uC.
Qdot-ITK were coupled to Ag85A following a previously described
protocol [37]. Briefly, 400 pmol of Qdot-ITK were mixed with
16 nmol of Ag85A and 1.6 mmol of EDC (N-(3-dimethyl-amino-
propyl)-N’-ethyl-carbodimide hydrochloride) (Sigma, St. Louis,
MO, USA) and the pH was adjusted to 7.4 and incubated for 1 h
at room temperature. Nanosep spin filters of 100-kilodalton cutoff
(Pall, East Hills, NY, USA) were washed first with 100 mlo f1m M
NTA (N,N-bis-(carboxymethyl)-L-lysine hydrate) (Sigma) and
secondly with 500 ml of Tris HCl buffer. After washing, the
conjugate was collected and stored at 4uC until use. To check if
conjugation had taken place and conjugate fluorescence, Qdot-ITK
and conjugated Qdot-ITK-Ag85A were separated by a 0.5%
agarose gel and visualized using ultraviolet light (Fig. 2e).
Due to ethical reasons, pregnant mice (3 per group) at day 11
were anesthetized with isofluorane and 100 ml of solution
containing 120–130 pmols of Qdot-ITK or Qdot-ITK-Ag85A
were injected s.c. We reasoned that there would be no major
differences in placental transfer between day 11 and day 14 of
gestation since mouse placenta from day 8.5 to day 10.5 is known
to be ready to exchange materials from the mother to the fetus
[38]. Also placenta examined from day 10 to day 18 of pregnancy
revealed that cells important for building three layers: the
labyrinth, the spongiotrophoblast, and the maternal deciduas,
are present during this period although variations in the number
and function of cells could be expected [39]. Mice were sacrificed
at 3, 24 and 48 h post-injection by cervical dislocation and skin,
kidneys, liver, lungs, and spleen as well as placentas from pregnant
females and whole fetuses were collected, washed with PBS and
embedded in OCT compound (Sakura, IMEB, San Marcos, CA,
USA). Sections (10 mm) were prepared using a cryostat (Leica,
Wetzlar, Germany) and fixed at 4uC with cold acetone, washed in
distilled water and mounted with Neo-Mount (Merck, Darmstadt,
Germany). The slides were observed with a fluorescence
microscope (Reichert Microscope, Depew, NY, USA) using green
light to visualize Qdot-ITK or Qdot-ITK-Ag85A conjugates.
Mononuclear cell isolation
One week after the last immunization with Ag85A or rHBHA,
lungs were collected in sterile PBS, cut into small pieces (2–3 mm)
and incubated for one hour at 37uC with collagenase type I (1 mg/
ml, Roche, Mannheim, Germany) and DNase (30 U/ml, Sigma).
Lung pieces were then crushed by using a glass homogenizer and
the cell suspension was passed through a 70 mm nylon membrane
(BD, Franklin Lakes, NJ USA) and subjected to gradient
separation using Lympholyte M (CEDARLANE laboratories,
Ontario, Canada). After centrifugation at 1500 g for 20 minutes,
the interface was collected and washed twice with PBS. Viable
cells were enumerated using trypan blue. Thereafter, cells were
cultured in complete DMEM medium containing 10% fetal calf
serum, 2 mM L-glutamine, 100 U/ml penicillin, 100 mg/ml
streptomycin and 2 mM sodium pyruvate (all from Invitrogen,
Paisley, UK).
In vitro Ag-restimulation of lymphocytes
Mononuclear cells were isolated from the lungs and plated
(2610
5 cells/well) in 96-well flat bottom plates (Costar, NY, USA)
and stimulated with rHBHA (5 mg/ml), Ag85A (10 mg/ml) or Con
A( 2mg/ml) for 72 h at 37uC, 5% CO2. Cell culture supernatant
was collected and stored at 220uC until tested for cytokines by
Enzyme-linked immuno sorbent assay (ELISA) assay.
IFN-c ELISA
A commercially available kit for IFN-c (Mabtech, Stockholm,
Sweden) was used to determine the cytokine levels in the culture
supernatants according to the manufacturer’s recommendations,
with slight modifications. Streptavidin conjugated to alkaline
phosphatase was used instead of horseradish peroxidase at 1:1000
Table 3. Immunization schedule.
Treatment
1 Nursing Mother2
Pregnant mice Offspring mice (2X)
++ Ag+
- + Ag2
++ Ag2
- + Ag+
-- A g 2
1Pregnant mice were treated with Ag85A or HBHA at the 2
nd week of gestation.
Offspring mice born to the mothers were immunized with Ag85A or HBHA at
week 1 and week 4 during postnatal age.
2Offspring mice were nursed by either treated (Ag+) or untreated (Ag2) mother
until week 3.
doi:10.1371/journal.pone.0009699.t003
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nitrophenyl phosphate (Sigma). Optical density (O.D.) was
measured in a multiscan ELISA reader at 405 nm and
concentrations were calculated from the standard curves estab-
lished with corresponding purified recombinant mouse IFN-c.
Data are presented as pg/ml concentration.
Detection of antibodies in serum
Antibodies in serum were measured by ELISA. High-binding
ELISA plates (Costar, high binding, NY, USA) were coated with
Ag85A (2 mg/ml) in carbonate-bicarbonate buffer (pH 9.6) and
incubated overnight (ON) at room temperature (RT). Plates were
washed four times with washing buffer (0.9% NaCl- 0.05%
Tween-20). After washing, samples from individual animals from
each group (3–4 mice/group) were serially diluted with a starting
dilution 1:200 and added to the antigen coated plates and then
incubated ON at RT. Following sample incubation, plates were
washed and incubated for 2 h at RT with alkaline-phosphatase
(ALP) labelled goat anti-mouse IgM or IgG (Southern Biotech,
Birmingham, USA), and the enzyme substrate reaction was
developed using p-nitrophenyl phosphate as substrate. Optical
density was measured in a multiscan reader at 405 nm.
Statistical analysis
Comparison between two experimental groups was done by
Student’s t test. p values of ,0.05, and ,0.01 were considered as
the levels of significance.
Supporting Information
Figure S1 Secondary antibody levels after priming with Ag85A.
Adult mice (3 animals per group) were immunized with Ag85A
formulated with or without CT in a 2- weeks interval. Serum
samples were collected after primary week 1 (W1) and week 2 (W2)
and secondary week 1 (W1) immunizations. Antigen-specific IgG
levels were determined by ELISA. Data showed mean O.D. 6 s.d.
of antibodies in serum of 3 mice. Broken line indicates the cut-off
level after primary immunization with or without CT.
Found at: doi:10.1371/journal.pone.0009699.s001 (0.03 MB
DOC)
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